KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in IntangiblesChange in InventoryDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Share-based Compensation: 2019-2025

Historic Share-based Compensation for BioNTech SE (BNTX) over the last 7 years, with Sep 2025 value amounting to $32.6 million.

  • BioNTech SE's Share-based Compensation fell 27.38% to $32.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.3 million, marking a year-over-year increase of 17.72%. This contributed to the annual value of $107.8 million for FY2024, which is 94.96% up from last year.
  • Per BioNTech SE's latest filing, its Share-based Compensation stood at $32.6 million for Q3 2025, which was down 10.24% from $36.3 million recorded in Q2 2025.
  • BioNTech SE's Share-based Compensation's 5-year high stood at $73.6 million during Q3 2021, with a 5-year trough of $9.2 million in Q1 2023.
  • For the 3-year period, BioNTech SE's Share-based Compensation averaged around $23.4 million, with its median value being $21.8 million (2024).
  • Per our database at Business Quant, BioNTech SE's Share-based Compensation surged by 269,441,239.67% in 2021 and then slumped by 71.97% in 2023.
  • BioNTech SE's Share-based Compensation (Quarterly) stood at $23.5 million in 2021, then decreased by 3.42% to $22.6 million in 2022, then plummeted by 32.54% to $15.3 million in 2023, then soared by 64.36% to $25.1 million in 2024, then declined by 27.38% to $32.6 million in 2025.
  • Its Share-based Compensation stands at $32.6 million for Q3 2025, versus $36.3 million for Q2 2025 and $23.2 million for Q1 2025.